RxDoctor Payments DataLook up a doctor →

Loren Morgan, MD

Interventional Cardiology · Columbia, SCNPI 1225340292

Payments from drug & device makers

$127,177in general payments, 2019–2025

Across 456 payments — averaging $278.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$119K
  • Abbott$3K
  • Medtronic$1K
  • Novartis$474
  • AstraZeneca$469
  • Johnson & Johnson$384
  • plus $3K from 28 others

What the payments were for

  • Speaking & faculty fees$38,75064%
  • Grants$1350%
  • Travel & lodging$10,37517%
  • Food & beverage$10,85718%
  • Education$720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$127,177 in reported general payments places this provider in the 85th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$543,076
Medicare patients
1,087
Services billed
5,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$133,949
Repatha SureclickEvolocumab85$101,810
XareltoRivaroxaban45$46,249
EntrestoSacubitril/Valsartan38$32,462
JardianceEmpagliflozin26$29,542
Praluent PenAlirocumab24$29,160
FarxigaDapagliflozin Propanediol31$17,758
BrilintaTicagrelor30$16,699
Metoprolol Succinate178$2,804
ClopidogrelClopidogrel Bisulfate244$2,788
Rosuvastatin Calcium148$2,761
Atorvastatin Calcium222$2,607
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine14$2,301
Clonidine24$1,471
Bumetanide23$1,465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$155$133,949182 claims
Johnson & JohnsonXarelto$384$46,24945 claims
AstraZenecaFarxiga, Brilinta$469$34,45761 claims
NovartisEntresto$474$32,46238 claims
Boehringer IngelheimJardiance$26$29,54226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →